{"generic":"Belinostat","drugs":["Beleodaq","Belinostat"],"mono":{"0":{"id":"jyd3s0","title":"Generic Names","mono":"Belinostat"},"1":{"id":"jyd3s1","title":"Dosing and Indications","sub":[{"id":"jyd3s1b4","title":"Adult Dosing","mono":"<ul><li>evaluate serum chemistry, including renal and hepatic function, prior to the first dose in each cycle and ensure the absolute neutrophil count is 1 x 10(9)\/L or greater and platelet count is 50 x 10(9)\/L or greater<\/li><li><b>Peripheral T-cell lymphoma (clinical), Relapsed or refractory:<\/b> 1000 mg\/m(2) IV infusion over 30 minutes on days 1 through 5 of a 21-day cycle, repeated until disease progression or toxicity<\/li><li><b>Peripheral T-cell lymphoma (clinical), Relapsed or refractory:<\/b> homozygous for UGT1A1*28 al&le;: initial dose, 750 mg\/m(2) IV infusion over 30 minutes on days 1 through 5 of a 21-day cycle, repeated until disease progression or toxicity<\/li><\/ul>"},{"id":"jyd3s1b5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"jyd3s1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, CrCl 39 mL\/min or less:<\/b> insufficient data to recommend a dose<\/li><li><b>hepatic impairment, moderate to severe:<\/b> insufficient data to recommend a dose<\/li><li><b>neutropenia (absolute neutrophile count [ANC] nadir 0.5 x 10(9)\/L or less with any platelet count):<\/b> interrupt and resume with a decrease in dose of 25% [750 mg\/m(2)] only when ANC is 1 x 10(9)\/L or greater and platelet count is 50 x 10(9)\/L or greater<\/li><li><b>recurrent neutropenia (ANC nadir less than 0.5 x 10(9)\/L with any platelet count):<\/b> after 2 dosage reductions, discontinue use<\/li><li><b>thrombocytopenia (platelet count less then 25 x 10(9)\/L with any ANC nadir):<\/b> interrupt and resume with a decrease in dose of 25% [750 mg\/m(2)] only when platelet count is 50 x 10(9)\/L or greater and ANC is 1 x 10(9)\/L or greater<\/li><li><b>recurrent thrombocytopenia (platelet count less then 25 x 10(9)\/L plus any ANC nadir):<\/b> after 2 dose reductions, discontinue use<\/li><li><b>nonhematologic toxicities (grade 3 or 4), excluding nausea, vomiting, and diarrhea:<\/b> interrupt and resume with a decrease in dose of 25% [750 mg\/m(2)] only when the toxicity is grade 2 or less<\/li><li><b>nausea, vomiting, or diarrhea (grade 3 or 4) with duration longer than 7 days despite supportive management:<\/b> interrupt and resume with a decrease in dose of 25% [750 mg\/m(2)] only when the toxicity is grade 2 or less<\/li><li><b>recurrent nonhematologic toxicities (grade 3 or 4):<\/b> after 2 dose reductions, discontinue use<\/li><\/ul>"},{"id":"jyd3s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Peripheral T-cell lymphoma (clinical), Relapsed or refractory<br\/>"}]},"3":{"id":"jyd3s3","title":"Contraindications\/Warnings","sub":[{"id":"jyd3s3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jyd3s3b10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- nausea, vomiting and diarrhea have been reported; antiemetic and antidiarrheal medications may be necessary<\/li><li>Hematologic:<\/li><li>-- thrombocytopenia, leukopenia (neutropenia and lymphopenia), and\/or anemia may occur; monitoring recommended; dose adjustment may be necessary<\/li><li>Hepatic:<\/li><li>-- fatal hepatotoxicity and liver function test abnormalities may occur; monitoring recommended; interrupt, adjust, or permanently discontinue therapy based on severity of hepatic toxicity<\/li><li>Immunologic:<\/li><li>-- serious and sometimes fatal infections, including pneumonia and sepsis, have been reported<\/li><li>-- do not administer to patients with an active infection<\/li><li>Reproductive:<\/li><li>-- pregnancy should be avoided; may cause fetal harm<\/li><li>Other:<\/li><li>-- tumor lysis syndrome has been reported; monitoring recommended<\/li><li>Concomitant use<\/li><li>-- avoid coadministration with strong inhibitors of UGT1A1<\/li><\/ul>"},{"id":"jyd3s3b11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"jyd3s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jyd3s4","title":"Drug Interactions","sub":{"1":{"id":"jyd3s4b14","title":"Major","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><\/ul>"}}},"5":{"id":"jyd3s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (20%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (23%), Diarrhea (23%), Nausea (42%), Vomiting (29%)<\/li><li><b>Hematologic:<\/b>Anemia (32%), Neutropenia<\/li><li><b>Other:<\/b>Fatigue (37%), Fever (35%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (11%)<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (11%), Febrile neutropenia, Leukopenia, Thrombocytopenia, Grade 3 or 4 (7%)<\/li><li><b>Hepatic:<\/b>Liver failure, Liver function tests abnormal<\/li><li><b>Renal:<\/b>Serum creatinine raised (More than 2%)<\/li><li><b>Respiratory:<\/b>Pneumonia (More than 2%)<\/li><li><b>Other:<\/b>Infectious disease (More than 2%), Multiple organ failure (More than 2%), Sepsis, Tumor lysis syndrome<\/li><\/ul>"},"6":{"id":"jyd3s6","title":"Drug Name Info","sub":{"0":{"id":"jyd3s6b17","title":"US Trade Names","mono":"Beleodaq<br\/>"},"2":{"id":"jyd3s6b19","title":"Class","mono":"Histone Deacetylase Inhibitor<br\/>"},"3":{"id":"jyd3s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jyd3s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jyd3s7","title":"Mechanism Of Action","mono":"Belinostat is a histone deacetylase inhibitor that induces cell-cycle arrest and\/or apoptosis of transformed cells with preferential cytotoxicity toward tumor cells via the removal of acetyl groups from lysine residues of histones and some non-histone proteins and the subsequent accumulation of acetylated histones and other proteins.<br\/>"},"8":{"id":"jyd3s8","title":"Pharmacokinetics","sub":{"1":{"id":"jyd3s8b24","title":"Distribution","mono":"Protein binding: 92.9% to 95.8% <br\/>"},"2":{"id":"jyd3s8b25","title":"Metabolism","mono":"<ul><li>Hepatic: extensive<\/li><li>Metabolites: belinostat amide, belinostat acid, methylbelinostat, and 3-anilinosulfonyl-benzenecarboxylic acid; activity unknown<\/li><li>Substrate primarily of UGT1A1; also a substrate of CYP2A6, CYP2C9, and CYP3A4; a likely substrate of P-glycoprotein<\/li><\/ul>"},"3":{"id":"jyd3s8b26","title":"Excretion","mono":"<ul><li>Renal: less than 2% unchanged in urine<\/li><li>Total body clearance: 1240 mL\/min<\/li><li>UGT1A1*28 al&le;; may have reduced UGT1A1 activity; clearance may be reduced<\/li><\/ul>"},"4":{"id":"jyd3s8b27","title":"Elimination Half Life","mono":"1.1 hours <br\/>"}}},"9":{"id":"jyd3s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>use precautions for cytotoxic agents<\/li><li>reconstitute vial with 9 mL of sterile water for injection to yield 50 mg\/mL solution<\/li><li>use within 12 hours of reconstitution if stored at ambient temperature (15 to 25 degrees C; 59 to 77 degrees F)<\/li><li>dilute desired dose in 250 mL NS<\/li><li>administer within 36 hours (including infusion time) if stored at ambient temperature (15 to 25 degrees C; 59 to 77 degrees F)<\/li><li>infuse via a 0.22 mcm inline filter over 30 minutes; may be extended to 45 minutes if needed<\/li><\/ul>"},"10":{"id":"jyd3s10","title":"Monitoring","mono":"<ul><li>partial or complete tumor response is indicative of efficacy<\/li><li>blood counts, at baseline and weekly during therapy, including differential<\/li><li>liver and renal function tests, before each treatment cycle<\/li><li>tumor lysis syndrome, in patients with advanced-stage disease or high tumor burden<\/li><\/ul>"},"11":{"id":"jyd3s11","title":"How Supplied","mono":"<b>Beleodaq<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/>"},"13":{"id":"jyd3s13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report symptoms of an infection or liver toxicity.<\/li><li>Tell patient to report symptoms of thrombocytopenia, leukopenia, or anemia.<\/li><li>Advise patient to report symptoms of tumor lysis syndrome.<\/li><li>Side effects may include nausea, vomiting, pyrexia, or fatigue.<\/li><\/ul>"}}}